16 known cases. View patent page →
Bright Data asserted claims 1 and 26 of the '319 patent against Oxylabs. A jury was instructed to determine infringement and validity, and a verdict form was filed on November 5, 2021.
This case involving Bright Data and Oxylabs was stayed and administratively closed.
This Inter Partes Review (IPR) case concerning patent 10257319 resulted in a Final Written Decision.
This Inter Partes Review (IPR) case concerning patent 10257319 resulted in a Final Written Decision.
This Inter Partes Review (IPR) case concerning patent 10257319 resulted in a Final Written Decision.
This Inter Partes Review (IPR) case concerning patent 10257319 resulted in a Final Written Decision.
This Inter Partes Review (IPR) case concerning patent 10257319 was procedurally terminated.
Institution was not granted for this Inter Partes Review (IPR) case concerning patent 10257319, and it was procedurally terminated.
Institution was not granted for this Inter Partes Review (IPR) case concerning patent 10257319, and it was procedurally terminated.
This case involving patent 10257319 is currently in litigation at the Court of Appeals for the Federal Circuit.
This case involving patent 10257319 is currently in litigation at the Court of Appeals for the Federal Circuit.
This case involving patent 10257319 is currently in litigation at the Court of Appeals for the Federal Circuit.
This case involving patent 10257319 is currently in litigation at the Court of Appeals for the Federal Circuit.
A critical case associated with patent 10257319 has been filed in the U.S. Supreme Court and is currently in litigation.
Action in E.D. Tex. asserting U.S. 10,469,614 and U.S. 10,257,319, 10,484,510, and 10,484,511 against Tefincom d/b/a NordVPN; the '968 patent was later added by amended complaint. The case was stayed and administratively closed on September 6, 2022 pending finality in Bright Data v. Teso, No. 2:19-cv-395.
Bright Data appealed the PTAB's final written decisions in IPR2022-00353 and related IPRs. The Federal Circuit consolidated the appeals and on August 1, 2025, affirmed the Board's role-based constructions, holding all challenged claims of the '344 and sibling patents 11,044,342; 10,257,319; and 10,484,510 unpatentable. Rehearing en banc was denied October 1, 2025.